Yuriko TOMITA

Dr. Yuriko TOMITA

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2022 in Pathogens
Verified
Journal Article
Open access
PDF file
KSKazuya Shirato
Kazuya Shirato
MKMasatoshi Kakizaki
Masatoshi Kakizaki
YTYuriko TOMITA
Yuriko TOMITA
MKMiyuki Kawase
Miyuki Kawase
Makoto TakedaMakoto Takeda
Makoto Takeda
In the ongoing coronavirus diseases 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), real-time RT-PCR based diagnostic assays have been used for the detection of infection, but the positive signal of real-time RT-PCR does not necessarily indicate the infectivity of the patient. Due to the unique replication system of the coronavirus, primer/probe sets targeted nucleocapsid (N) and spike (S) protein detect the abundantly synthesized subgenomic RNAs as well as the virus genome, possibly making the assay unsuitable for estimation of the infectivity of the specimen, although it has an advantage for the diagnostic tests. In this study, the primer/probe set targeting the open reading frame 1a (ORF1a) gene was developed to specifically detect viral genomic RNA. Then the relation between the ORF1a signal and infectivity of the clinical specimens was validated by virus isolation using VeroE6 cells, which constitutively express transmembrane protease, serine 2, (VeroE6/TMPRSS2). The analytical sensitivity of developed ORF1a set was similar to that of previously developed N and S sets. Nevertheless, in the assay of the clinical specimen, detection rate of the ORF1a gene was lower than that of the N and S genes. These data indicated that clinical specimens contain a significant amount of subgenomic RNAs. However, as expected, the isolation-succeeded specimen always showed an RT-PCR-positive signal for the ORF1a gene, suggesting ORF1a detection in combination with N and S sets could be a more rational indicator for the possible infectivity of the clinical specimens.

27 February 2025 in Viruses
Verified
Journal Article
Open access
PDF file
YTYuriko TOMITA
Yuriko TOMITA
HOHiyori Okura
Hiyori Okura
RMRika Mochizuki
Rika Mochizuki
MNmanami negoro
manami negoro
TYTakuya Yano
Takuya Yano
HHHideki Hasegawa
Hideki Hasegawa
The Coronavirus disease 2019 (COVID-19) pandemic significantly impacted the circulation patterns of respiratory viruses worldwide. To better understand viral circulation patterns during the transition from pandemic to endemic phase, we conducted comprehensive respiratory virus surveillance in Mie Prefecture, Japan, during 2021–2023, coinciding with the Delta-to-Omicron transition of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). We collected respiratory specimens from acute respiratory infection patients in medical institutions, detecting 19 respiratory viruses using real-time PCR in 1573 valid samples out of 1605 specimens. Demographic and clinical data were available for some specimens. SARS-CoV-2 Omicron strains showed a peak positivity of 15–25% during the epidemic, while respiratory syncytial virus and human rhinovirus/enterovirus exhibited one to two annual epidemic peaks up to 57%, and human adenovirus maintained a positivity rate of 5–20% throughout the year. Age-dependent analysis revealed the significant detection of multiple viruses, particularly in children under 2 years, with up to six viruses detected simultaneously in those under 5 years. Our findings demonstrate varied respiratory virus prevalence patterns, with some viruses remaining active during the Omicron epidemic, suggesting its limited impact on other viruses. This comprehensive approach should enhance the understanding of respiratory virus epidemic dynamics and inform public health strategies.

23 February 2026 in Viruses
Verified
Journal Article
Open access
PDF file
YTYuriko TOMITA
Yuriko TOMITA
KMKaya Miyazaki
Kaya Miyazaki
RMRika Mochizuki
Rika Mochizuki
HHHideki Hasegawa
Hideki Hasegawa
Molnupiravir induces mutations that render severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication-competent through error catastrophe mechanisms. Previous studies showed no resistant virus emergence during prolonged molnupiravir treatment, with no resistant variants reported. However, these approaches were limited by genetic uniformity at passage initiation. To investigate viral population dynamics under enhanced genetic diversity, we employed mutagenic pre-treatment using 5-fluorouracil (5-FU) and favipiravir to generate diverse quasi-species populations before molnupiravir selection pressure. Viral populations were treated with stepwise increasing molnupiravir concentrations (10 μM ⟶ 25 μM ⟶ 40 μM) over ten serial passages. Viral detectability, plaque morphology, and mutation accumulation were analyzed using molecular and sequencing approaches. Only high-concentration favipiravir (1000 μM) pre-treatment maintained detectable viral RNA through ten passages under 40 μM molnupiravir, while favipiravir (500 μM) and 5-FU groups became undetectable after passage 6. Surviving populations formed extremely small plaques with markedly reduced replication capacity. Next-generation sequencing revealed extensive mutation accumulation across viral proteins, including polymerase proteins. Individual viable virus isolation was unsuccessful, and large-scale propagation could not be achieved. These findings demonstrate apparent survival rather than true resistance to molnupiravir, characterized by severely compromised viral fitness.